2. UroToday Home
  3. Video Lectures

Imaging Center Videos

Co-PSMA Trial Explores Tracer for Detecting Recurrence After Radical Prostatectomy - Louise Emmett
The Co-PSMA Trial: Comparing PSMA PET Tracers in Biochemically Recurrent Prostate Cancer - Louise Emmett
Balancing MRI Sensitivity and Specificity in Prostate Cancer Staging - Georgios Agrotis
PRIME Trial Compares Biparametric MRI to Multiparametric MRI for Prostate Cancer Diagnosis - Francesco Giganti & Andrei Purysko
Integrating PSMA PET Imaging: From Interpretation to Systemic Therapy Selection in Castration-Resistant Prostate Cancer - Oliver Sartor
Early-Phase Study Investigates Copper-61 PSMA PET for Prostate Cancer Imaging - Gary Ulaner
The Use of a Long-Axial PET Scanner for PSMA Imaging in Prostate Cancer - Rodney Hicks
Study Evaluates PSMA-PET-Based Nomograms for Prostate Cancer Prognosis - Kambiz Rahbar
Radiopharmaceutical Therapies: Safety, Education, and Collaboration in Oncology - Heather Jacene & Neha Vapiwala
Surgical Outcomes in High-Risk Prostate Cancer: PSMA-PET vs Conventional Imaging - Alessandro Viti
PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman
Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett
CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore
PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan
COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo
Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman
COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala
The 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer - Faina Shtern
PSMA PET's Influence on Prostate Cancer Studies - Jeremie Calais
Setting a Global Standard: Unveiling the New PSMA PET/CT Procedure Guideline - Wolfgang Fendler & Ken Herrmann
Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy - Ken Herrmann
Improving Appropriate Utilization of Imaging in Prostate Cancer Patients: A Discussion on the RADAR Articles - E. David Crawford
PYLARIFY PET Imaging: A Transformative Resource for Urologists and Radiologists - Michael Kipper
Unraveling Prostate Cancer Response: PSMA PET Sheds New Light on Treatment Effectiveness - Andrei Gafita & Wolfgang Fendler
The Role of Imaging Before and After Diagnosis of Localized Prostate Cancer - Masoom Haider
Smarter Screening In Prostate Cancer - Sigrid Carlsson
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer - Wolfgang Fendler and Andrei Gafita
Future Perspectives in Prostate Imaging in Developing Countries - Ronaldo Hueb Baroni
PSMA PET CT Derived Risk-Stratification Tool for High-risk Prostate Cancer - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Radiotherapy Guided by PSMA PET Molecular Imaging - Juan Galvis Serrano
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen
Results from the Phase 3 SPOTLIGHT Trial of 18F-rhPSMA-7.3 in Recurrent Prostate Cancer - David Schuster
Clinical Trial Equity in Radionuclide Treatment for Prostate Cancer - Joseph Osborne
PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor
NCCN Guidelines On PSMA Molecular Imaging - Tanya Dorff
Understanding Physiological PSMA Biodistribution - Jeremie Calais
Developing a Theranostics Program, The Nebraska Cancer Specialists Model - Samuel Mehr
Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris
18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer (CONDOR) Journal Club - Christopher Wallis & Zachary Klaassen
PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris
The Impact on Patient Care and Clinical Outcomes Gallium 68 PSMA-11 in Suspected Prostate Cancer Metastasis - Jeremie Calais
68Ga-PSMA-11 PET approved in Biochemical Recurrent Prostate Cancer - Jeremie Calais
68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope
Changing the Standard of Care in Prostate Cancer with Advances in Nuclear Medicine, PET and Theranostics Symposium - Rob Flavell
CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer - Michael J. Morris
PSMA PET/CT Imaging for Staging High-risk Prostate Cancer Prior to Curative-intent Surgery or Radiotherapy (proPSMA) - Michael Hofman and Declan Murphy
PSMA PET Diagnostic Imaging in the Current Era - Jeremie Calais
Initial Experience with Actinium- 225 PSMA in Advanced Prostate Cancer - Machaba Michael Sathekge
Advances in PSMA-directed Radionuclide Therapy - Howard Soule
The Use of Novel Imaging Methods in Prostate Cancer - Stefano Fanti
Insights on Nuclear Imaging for Prostate Cancer- Stefano Fanti
Incorporate Next Generation Imaging Tools Into Clinical Practice - Piet Ost
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
Advantages of PSMA PET in APC Imaging Presentation - Stefano Fanti
PSMA PET CT, A Mixed Blessing - Interview with Ian Davis
Imaging and Flare Responses When Assessing Patients with Metastatic Castration-Resistant Prostate Cancer - Anwar Padhani
Gold Nanoparticles Used in Photothermal Therapy for Prostate Tumors- Art Rastinehad
Imaging Bone (Flare) Responses in Advanced Prostate Cancer Presentation - Anwar Padhani
Credentialing Imaging as an Outcome Measure in Prostate Cancer - Lawrence H. Schwartz and Michael J. Morris
SNMMI Osseous Scintigraphy - Ephraim E. Parent
Case-based Approaches: PSMA and Personalized Prostate Cancer Care - Frankis Almaguel
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Bombesin - A New Frontier for Prostate Cancer Imaging - Andrei Iagaru
PSMA Theranostics and Personalized Prostate Cancer Care- Frankis Almaguel
Focal Therapy - Art Rastinehad
Prostate Cancer Diagnosis and Treatment: Incorporating New PET imaging and Theranostic Approaches - Robert Flavell
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
3D Prostate Gland Uptake of 18F Choline PET CT - Association with Overall Survival in Patients with Hormone-naive Prostate Cancer - May Sadik
Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava
18F Fluorocholine PET-Whole Body MR in the Staging of High Risk Prostate Cancer - Ur Metser
68Ga PSMA 11 PET MRI in Intermediate and High Risk Prostate Cancer - Claudia Zacharias
Incremental Value of 11C Acetate Over 68Ga-PSMA PET CT for Prostate Cancer Patients - Sirong Chen
Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman
A Review of Imaging Modalities in Prostate Cancer - Peter Pinto
Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro
Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo
The Incredible Shrinking nmCRPC - Phillip Koo